Overview Dividends

(SGRY) Surgery Partners - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US86881A1007

Surgery Centers, Emergency Rooms, Urgent Care

SGRY EPS (Earnings per Share)

EPS (Earnings per Share) of SGRY over the last years for every Quarter: "2020-09-30": -0.53, "2020-12-31": 0.09, "2021-03-31": -0.3, "2021-06-30": -0.0016, "2021-09-30": -0.05, "2021-12-31": 0.23, "2022-03-31": -0.09, "2022-06-30": -0.03, "2022-09-30": -0.02, "2022-12-31": 0.27, "2023-03-31": 0.08, "2023-06-30": 0.28, "2023-09-30": 0.19, "2023-12-31": 0.44, "2024-03-31": 0.1, "2024-06-30": 0.21, "2024-09-30": -0.2512, "2024-12-31": 0.44, "2025-03-31": 0.04, "2025-06-30": 0.17,
EPS Growth (3Y CAGR): 22.73%
EPS Trend (3Y Correlation): -2.8%

SGRY Revenue

Revenue of SGRY over the last years for every Quarter: 2020-09-30: 496.1, 2020-12-31: 548.3, 2021-03-31: 512.4, 2021-06-30: 543.3, 2021-09-30: 559.2, 2021-12-31: 610.2, 2022-03-31: 596.2, 2022-06-30: 615.4, 2022-09-30: 620.6, 2022-12-31: 707.1, 2023-03-31: 666.2, 2023-06-30: 667.6, 2023-09-30: 674.1, 2023-12-31: 735.4, 2024-03-31: 717.4, 2024-06-30: 762.1, 2024-09-30: 770.4, 2024-12-31: 864.4, 2025-03-31: 776, 2025-06-30: 826.2,
Revenue Growth (3Y CAGR): 10.97%
Revenue Trend (3Y Correlation): 89.6%

Description: SGRY Surgery Partners

Surgery Partners Inc (NASDAQ:SGRY) operates a network of surgical facilities across the US, offering various non-emergency surgical procedures through ambulatory surgery centers and surgical hospitals. Their service portfolio includes specialties like orthopedics, ophthalmology, and gastroenterology, as well as ancillary services such as emergency departments, physician practices, and anesthesia services.

To evaluate SGRYs performance, key performance indicators (KPIs) such as revenue growth, same-facility revenue growth, and EBITDA margin are crucial. The companys ability to expand its network through strategic acquisitions and organic growth will be vital in driving future performance. Additionally, SGRYs operational efficiency, measured by metrics like revenue per procedure and cost per procedure, will impact its profitability. The companys leverage ratio and debt servicing capabilities should also be monitored to assess its financial health.

From a valuation perspective, SGRYs Price-to-Book ratio and Enterprise Value-to-EBITDA (EV/EBITDA) multiples can be used to gauge its relative attractiveness compared to industry peers. Furthermore, analyzing SGRYs cash flow generation and its ability to invest in growth initiatives or return capital to shareholders via dividends or share buybacks will be essential in understanding its overall investment potential.

SGRY Stock Overview

Market Cap in USD 2,764m
Sub-Industry Health Care Facilities
IPO / Inception 2015-10-01

SGRY Stock Ratings

Growth Rating -44.3%
Fundamental 47.6%
Dividend Rating -
Return 12m vs S&P 500 -41.4%
Analyst Rating 4.42 of 5

SGRY Dividends

Currently no dividends paid

SGRY Growth Ratios

Growth Correlation 3m 32.3%
Growth Correlation 12m -44.9%
Growth Correlation 5y -59.8%
CAGR 5y -6.71%
CAGR/Max DD 3y -0.12
CAGR/Mean DD 3y -0.20
Sharpe Ratio 12m -0.93
Alpha 0.00
Beta 0.941
Volatility 40.96%
Current Volume 1400.3k
Average Volume 20d 1182.7k
Stop Loss 21.1 (-3.2%)
Signal -0.37

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income (-180.4m TTM) > 0 and > 6% of Revenue (6% = 194.2m TTM)
FCFTA 0.01 (>2.0%) and ΔFCFTA -1.54pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 16.43% (prev 15.95%; Δ 0.49pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.03 (>3.0%) and CFO 263.9m > Net Income -180.4m (YES >=105%, WARN >=100%)
Net Debt (3.63b) to EBITDA (522.3m) ratio: 6.95 <= 3.0 (WARN <= 3.5)
Current Ratio 1.93 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (127.0m) change vs 12m ago 0.67% (target <= -2.0% for YES)
Gross Margin 23.74% (prev 24.02%; Δ -0.27pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 41.92% (prev 38.58%; Δ 3.34pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 1.55 (EBITDA TTM 522.3m / Interest Expense TTM 233.0m) >= 6 (WARN >= 3)

Altman Z'' 0.25

(A) 0.07 = (Total Current Assets 1.11b - Total Current Liabilities 573.3m) / Total Assets 7.95b
(B) -0.10 = Retained Earnings (Balance) -777.5m / Total Assets 7.95b
(C) 0.05 = EBIT TTM 361.6m / Avg Total Assets 7.72b
(D) -0.18 = Book Value of Equity -789.5m / Total Liabilities 4.38b
Total Rating: 0.25 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 47.55

1. Piotroski 2.50pt = -2.50
2. FCF Yield 1.53% = 0.77
3. FCF Margin 2.90% = 0.73
4. Debt/Equity 2.07 = 0.67
5. Debt/Ebitda 6.92 = -2.50
6. ROIC - WACC (= -3.61)% = -4.51
7. RoE -10.06% = -1.68
8. Rev. Trend 89.56% = 6.72
9. EPS Trend -2.83% = -0.14

What is the price of SGRY shares?

As of September 18, 2025, the stock is trading at USD 21.79 with a total of 1,400,289 shares traded.
Over the past week, the price has changed by +1.54%, over one month by -3.11%, over three months by +7.18% and over the past year by -30.56%.

Is Surgery Partners a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Surgery Partners (NASDAQ:SGRY) is currently (September 2025) a stock to sell. It has a ValueRay Fundamental Rating of 47.55 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SGRY is around 18.88 USD . This means that SGRY is currently overvalued and has a potential downside of -13.35%.

Is SGRY a buy, sell or hold?

Surgery Partners has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy SGRY.
  • Strong Buy: 8
  • Buy: 1
  • Hold: 3
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the SGRY price?

Issuer Target Up/Down from current
Wallstreet Target Price 30.8 41.4%
Analysts Target Price 30.8 41.4%
ValueRay Target Price 20.3 -7%

Last update: 2025-09-18 04:41

SGRY Fundamental Data Overview

Market Cap USD = 2.76b (2.76b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 250.1m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 22.2717
P/S = 0.8539
P/B = 1.5811
P/EG = 1.66
Beta = 1.765
Revenue TTM = 3.24b USD
EBIT TTM = 361.6m USD
EBITDA TTM = 522.3m USD
Long Term Debt = 3.47b USD (from longTermDebt, last quarter)
Short Term Debt = 149.6m USD (from shortTermDebt, last quarter)
Debt = 3.61b USD (Calculated: Short Term 149.6m + Long Term 3.47b)
Net Debt = 3.63b USD (from netDebt column, last quarter)
Enterprise Value = 6.13b USD (2.76b + Debt 3.61b - CCE 250.1m)
Interest Coverage Ratio = 1.55 (Ebit TTM 361.6m / Interest Expense TTM 233.0m)
FCF Yield = 1.53% (FCF TTM 94.0m / Enterprise Value 6.13b)
FCF Margin = 2.90% (FCF TTM 94.0m / Revenue TTM 3.24b)
Net Margin = -5.57% (Net Income TTM -180.4m / Revenue TTM 3.24b)
Gross Margin = 23.74% ((Revenue TTM 3.24b - Cost of Revenue TTM 2.47b) / Revenue TTM)
Tobins Q-Ratio = -7.76 (set to none) (Enterprise Value 6.13b / Book Value Of Equity -789.5m)
Interest Expense / Debt = 1.88% (Interest Expense 67.9m / Debt 3.61b)
Taxrate = 91.50% (134.6m / 147.1m)
NOPAT = 30.7m (EBIT 361.6m * (1 - 91.50%))
Current Ratio = 1.93 (Total Current Assets 1.11b / Total Current Liabilities 573.3m)
Debt / Equity = 2.07 (Debt 3.61b / last Quarter total Stockholder Equity 1.75b)
Debt / EBITDA = 6.92 (Net Debt 3.63b / EBITDA 522.3m)
Debt / FCF = 38.46 (Debt 3.61b / FCF TTM 94.0m)
Total Stockholder Equity = 1.79b (last 4 quarters mean)
RoA = -2.27% (Net Income -180.4m, Total Assets 7.95b )
RoE = -10.06% (Net Income TTM -180.4m / Total Stockholder Equity 1.79b)
RoCE = 6.88% (Ebit 361.6m / (Equity 1.79b + L.T.Debt 3.47b))
RoIC = 0.59% (NOPAT 30.7m / Invested Capital 5.22b)
WACC = 4.20% (E(2.76b)/V(6.38b) * Re(9.48%)) + (D(3.61b)/V(6.38b) * Rd(1.88%) * (1-Tc(0.92)))
Shares Correlation 3-Years: 75.76 | Cagr: 3.29%
Discount Rate = 9.48% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.92% ; FCFE base≈138.0m ; Y1≈170.3m ; Y5≈290.5m
Fair Price DCF = 29.78 (DCF Value 3.82b / Shares Outstanding 128.2m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -2.83 | EPS CAGR: 22.73% | SUE: 0.05 | # QB: 0
Revenue Correlation: 89.56 | Revenue CAGR: 10.97% | SUE: 0.86 | # QB: 1

Additional Sources for SGRY Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle